Skip to content

Study · Non-randomized trial · n = 44 · 2010

3 results

Changes in cross-sectional area of spinal canal and vertebral body under 2 years of teriparatide treatment: results from the EUROFORS study.

Schnell R, Graeff C, Krebs A, Oertel H, Glüer CC

Calcified tissue international23 Jun 2010Cited by 6 (Europe PMC)

PMID20571786 (opens in a new tab)PMCIDPMC2903699 (opens in a new tab)DOI10.1007/s00223-010-9386-8 (opens in a new tab)PepBankPUB-20571786
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, spinal canal area increased marginally by 0.9% during teriparatide treatment over 24 months.

    In plain wordsIn women with osteoporosis, spinal canal area increased slightly from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpinal canal cross-sectional area
    Study

    n = 44

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/day · 24 monthsAs given in this study (human).

    Measurements

    Spinal canal area change
    0.9%
    24 months
    Spinal canal area change
    2.6 mm(2)
    24 months
    Spinal canal area change range
    −0.5 to 3.1%
    24 months
    Spinal canal area change range
    −2 to 8 mm(2)
    24 months

    Source sentences

    Summary
    The CSA of the spinal canal did not decrease but increased marginally by 0.9% (2.6 mm(2)) over 24 months (P < 0.001), with a range from -0.5% (-2 mm(2)) to 3.1% (+8 mm(2)).
    1 context sentence
    Summary · context
    High-resolution computed tomography (HRCT) scans of vertebra T12 were obtained at baseline and after 6, 12, and 24 months of teriparatide treatment (20 microg/day) from 44 postmenopausal women with established osteoporosis participating in the prospective, randomized EUROFORS study.
  2. 02HumanNon-randomized trialSafety outcome

    In postmenopausal women receiving teriparatide, slice-by-slice analysis found no clinically relevant spinal canal narrowing.

    In plain wordsIn women receiving teriparatide, detailed scans found no clinically relevant spinal canal narrowing.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeClinically relevant spinal canal narrowing
    Study

    n = 44

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/day · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Even when analyzing the spinal CSA on a slice-by-slice basis, no clinically relevant narrowing of the spinal canal was observed.
    1 context sentence
    Summary · context
    High-resolution computed tomography (HRCT) scans of vertebra T12 were obtained at baseline and after 6, 12, and 24 months of teriparatide treatment (20 microg/day) from 44 postmenopausal women with established osteoporosis participating in the prospective, randomized EUROFORS study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, vertebral body area increased by 0.7% during teriparatide treatment over 24 months.

    In plain wordsIn women with osteoporosis, vertebral body area increased slightly from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseVertebral body cross-sectional area
    Study

    n = 44

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/day · 24 monthsAs given in this study (human).

    Measurements

    Vertebral body area change
    0.7%
    24 months
    Vertebral body area change
    5.7 mm(2)
    24 months
    Vertebral body area change range
    −0.4 to 1.6%
    24 months
    Vertebral body area change range
    −3 to 14 mm(2)
    24 months

    Source sentences

    Summary
    For vertebral bodies, the CSA increased by 0.7% (5.7 mm(2)) over 24 months (P < 0.001), with a range from -0.4% (-3 mm(2)) to 1.6% (+14 mm(2)).
    1 context sentence
    Summary · context
    High-resolution computed tomography (HRCT) scans of vertebra T12 were obtained at baseline and after 6, 12, and 24 months of teriparatide treatment (20 microg/day) from 44 postmenopausal women with established osteoporosis participating in the prospective, randomized EUROFORS study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.